Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment develops, manufactures, and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products, and transdermals across a range of therapeutic categories. The Specialty segment is involved in the development, promotion, distribution, and sale of branded pharmaceutical products with focus on central nervous system disorders, endocrinology, parasitic infections, and other therapeutic areas. It also offers Emverm, a chewable tablet for the treatment of pinworm, whipworm, common roundworm, common hookworm, and American hookworm in single or mixed infections; Rytary to treat Parkinson's disease; and Unithroid for the treatment of hypothyroidism. The AvKARE segment provides pharmaceuticals, medical and surgical products, and services primarily to governmental agencies, the Department of Defense, and the Department of Veterans Affairs. It is also involved in the wholesale distribution of bottle and unit dose pharmaceuticals under the AvKARE and AvPAK names, as well as medical and surgical products; and packaging and wholesale distribution of pharmaceuticals and vitamins to its retail and institutional customers. The company sells its products through wholesalers, distributors, hospitals, chain pharmacies, and individual pharmacies. It operates in the United States, India, Ireland, and internationally. The company was formerly known as Atlas Holdings, Inc. and changed its name to Amneal Pharmaceuticals, Inc. in 2018. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey.

	Dec '16	Dec '17	Dec '18	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
asset turnover		0.77 -	0.38 50.40%	0.44 16.12%	0.50 12.11%	0.53 6.85%	0.58 9.57%	0.69 18.38%
cash conversion cycle		289.08 -	83.80 71.01%	99.80 19.10%	84.38 15.45%	89.83 6.46%	120.56 34.21%	200.04 65.93%
cash per share		0.65 -	1.68 159.70%	1.14 31.75%	2.32 102.30%	1.66 28.14%	0.17 89.66%	0.52 202.01%
company equity multiplier		-3.48 -	4.86 239.59%	10.57 117.69%	11.61 9.87%	10.74 7.56%	20.65 92.36%	175.55 750.09%
days of inventory outstanding		204.29 -	176.30 13.70%	109.23 38.04%	131.28 20.19%	134.84 2.71%	135.70 0.63%	134.90 0.59%
days of payables outstanding		50.36 -	198.37 293.92%	145.46 26.67%	164.20 12.88%	160.73 2.11%	137.60 14.39%	33.31 75.79%
days of sales outstanding		135.15 -	105.86 21.67%	136.04 28.50%	117.29 13.78%	115.72 1.34%	122.47 5.83%	98.46 19.61%
dividend yield	0.13 -	0.20 48.86%	0.11 45.83%
ebit per revenue	0.28 -	0.24 15.25%	-0.01 104.99%	-0.08 614.26%	0.05 154.14%	0.10 118.45%	0.09 6.62%	0.09 8.51%
ebt per ebit	0.75 -	0.70 7.31%	10.30 1,374.22%	1.60 84.45%	-0.39 124.49%	0.15 138.19%	-1.20 901.69%	-0.20 83.60%
effective tax rate	0.03 -	0.01 53.56%	0.01 39.98%	-1.74 24,965.22%	2.92 267.58%	0.36 87.76%	-0.03 107.52%	-0.21 681.71%
enterprise value multiple		12.26 -	10.10 17.60%	46.58 361.11%	9.38 79.87%	7.55 19.50%	6.98 7.48%	8.92 27.71%
fixed asset turnover		2.12 -	3.06 43.92%	2.67 12.64%	3.35 25.39%	3.28 2.13%	3.75 14.57%	4.35 15.91%
free cash flow per share	-0.08 -	1.04 1,356.19%	1.20 15.27%	-0.72 160.21%	2.12 392.79%	1.27 40.12%	-0.17 113.30%	1.57 1,029.03%
gross profit margin	0.59 -	0.51 13.24%	0.43 15.37%	0.22 49.62%	0.32 45.30%	0.37 16.46%	0.35 3.43%	0.34 3.35%
interest coverage	5.15 -	3.45 33.07%	-0.14 103.97%	-0.82 496.23%	0.62 176.42%	1.53 145.83%	1.30 15.06%	0.97 25.57%
inventory turnover		1.79 -	2.07 15.88%	3.34 61.41%	2.78 16.80%	2.71 2.64%	2.69 0.63%	2.71 0.59%
long term debt to capitalization		1.38 -	0.75 45.83%	0.89 18.52%	0.89 0.67%	0.89 0.90%	0.94 5.86%	0.99 5.88%
net income per ebt	0.97 -	0.98 1.37%	0.84 14.44%	2.74 227.33%	-1.92 169.94%	0.64 133.55%	1.03 59.68%	2.09 103.12%
net profit margin	0.20 -	0.16 20.36%	-0.10 162.93%	-0.37 263.62%	0.03 109.27%	0.01 72.01%	-0.12 1,295.47%	-0.04 69.53%
operating cash flow per share	1.00 -	2.04 103.53%	1.97 3.56%	0.01 99.34%	2.57 19,816.56%	1.62 36.83%	0.43 73.44%	1.96 354.92%
operating cycle		339.44 -	282.16 16.87%	245.27 13.08%	248.58 1.35%	250.56 0.80%	258.16 3.03%	233.36 9.61%
operating profit margin	0.28 -	0.24 15.25%	-0.01 104.99%	-0.08 614.26%	0.05 154.14%	0.10 118.45%	0.09 6.62%	0.09 8.51%
payables turnover		7.25 -	1.84 74.61%	2.51 36.37%	2.22 11.41%	2.27 2.16%	2.65 16.81%	10.96 313.06%
pretax profit margin	0.21 -	0.17 21.44%	-0.12 173.55%	-0.14 11.09%	-0.02 86.74%	0.01 183.43%	-0.11 848.65%	-0.02 85.00%
price fair value		-4.96 -	1.92 138.74%	1.84 4.41%	1.95 6.39%	1.94 0.49%	1.63 16.01%	54.05 3,210.46%
receivables turnover		2.70 -	3.45 27.66%	2.68 22.18%	3.11 15.98%	3.15 1.36%	2.98 5.51%	3.71 24.39%
return on assets		0.12 -	-0.04 131.21%	-0.16 322.24%	0.02 110.40%	0.01 70.09%	-0.07 1,409.86%	-0.02 63.93%
return on capital employed		0.23 -	-0.01 102.21%	-0.04 751.76%	0.03 162.07%	0.06 134.23%	0.07 5.67%	0.08 14.84%
return on equity		-0.43 -	-0.19 56.43%	-1.74 819.18%	0.20 111.42%	0.05 72.35%	-1.38 2,619.65%	-4.25 206.61%
total debt to capitalization		1.35 -	0.75 44.47%	0.89 18.45%	0.90 0.72%	0.89 0.91%	0.94 5.91%	0.99 5.71%

NYSE:AMRX

Amneal Pharmaceuticals, Inc.

Last Close

6.21

03/05 20:00

Market Cap

1.68B

Beta: 1.32

Volume Today

3.83M

Avg: 1.09M

PE Ratio

151.43

PFCF: 12.36